← Back to Clinical Trials
Recruiting NCT05623306

SEEG-Guided DBS for OCD

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Obsessive-Compulsive Disorder
Sponsor Katherine Scangos
Study Type INTERVENTIONAL
Phase N/A
Enrollment 10
Sex ALL
Min Age 22 Years
Max Age 75 Years
Start Date 2023-04-13
Completion 2028-03-01
Interventions
PMT Stereoencephalography (SEEG)Vercise Genus™ Deep Brain Stimulation (DBS) System or Percept™ PC Neurostimulation System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a multi-site, double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open label stimulation for an additional 6 months. The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of DBS surgery and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open label treatment.

Eligibility Criteria

Inclusion Criteria: 1. ≥ 22 years and ≤ 75 years of age, at the time of screening 2. Chronic (\> five years preceding the date of enrollment) OCD, diagnosed as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines (DSM-5) 1. Presence of obsessions, compulsions, or both 2. Time-consuming obsessions and compulsions that take more than one hour a day or cause clinically significant distress or impairment in social, occupational, or other important areas of functioning 3. Obsessive-compulsive symptoms that are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition 4. Disturbance not better explained by the symptoms of another mental disorder listed in the DSM-5 3. Severe OCD symptoms, as defined by Y-BOCS I score of ≥ 28, within two weeks prior to enrollment 4. Lack of adequate response to a history of the following treatments, based on information from any of the following: (a) the c

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}